Traws Pharma, Inc. (TRAW)
| Market Cap | 18.61M |
| Revenue (ttm) | 226,000 |
| Net Income (ttm) | -140.79M |
| Shares Out | 3.03M |
| EPS (ttm) | -141.78 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 101,606 |
| Open | 6.79 |
| Previous Close | 6.84 |
| Day's Range | 6.06 - 7.13 |
| 52-Week Range | 4.06 - 27.50 |
| Beta | 1.13 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 14, 2024 |
About TRAW
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-k... [Read more]
Financial Performance
In 2023, Traws Pharma's revenue was $226,000, a change of 0.00% compared to the previous year's $226,000. Losses were -$18.95 million, -0.08% less than in 2022.
Financial numbers in USD Financial StatementsNews
Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program
SAN DIEGO , Jan. 10, 2025 /PRNewswire/ -- Expert Systems, a hybrid AI enabled drug discovery and development accelerator, announced a significant milestone in a development of Traws Pharma, Inc. 's (N...
Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval
Initial tranche of $20 Million extends cash runway into 1H26, subsequent tranche of up to $52.6 Million will provide for runway 3+ years enabling the company to reach both near-term and long-term valu...
Traws Pharma stock soars 200% on encouraging bird flu drug data
Shares of Traws Pharma Inc (NASDAQ: TRAW) more than tripled today after reporting encouraging early-stage data for its tivoxavir marboxil as a treatment of H5N1 bird flu. The investigational drug demo...
Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu
Investigational agent in development for treatment or prevention of H5N1 Bird Flu Phase 1 dosing completed in healthy volunteers Potent inhibition of drug-resistant and bird flu viruses in vitro In ...
Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results
NEWTOWN, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral disease...
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
Investigational agent in development as a one dose treatment or prevention of seasonal and pandemic influenza A dose ranging, Phase 1 study in healthy volunteers demonstrated positive tolerability res...
Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
Ratutrelvir was well-tolerated for 10 days and achieved consistent plasma levels in the predicted therapeutic window, without the need for co-administration of ritonavir
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors
Experienced Life Sciences Executive Brings Strategic Expertise to Support Traws' Further Transformation and Growth
Traws Pharma, Inc. Announces Special Shareholders Meeting Results
Three proposals, including a reverse stock split, were submitted and approved Traws Board subsequently approved a 1-for-25 reverse stock split Traws' shares expected to begin trading on a split-adjust...
Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript
Traws Pharma, Inc. (NASDAQ:TRAW) Corporate Update Call August 15, 2024 8:00 AM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Werner Cautreels - CEO Mark Guerin - CFO Conference Call Par...
Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights
Merger with Trawsfynydd Therapeutics, Inc (“Trawsfynydd”) and concurrent private placement of $14 million (cash runway to support planned operations through year end), with recently achieved clinical ...
Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET
NEWTOWN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral disease...
Traws Pharma Announces New Employee Inducement Grants
NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new employees who joined Traws in connection ...
Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024
NEWTOWN, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and develo...
Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's
Differentiated profile of narazaciclib supported by positive results of studies demonstrating broad multi-kinase activity, with significant anti-tumor activity and increased anti-tumor immunity, compa...
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference
NEWTOWN, Pa., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developin...
Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript
Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Steve Fruchtman - President and CEO Vi...
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
Narazaciclib progressing towards registrational studies; target engagement and acceptable safety profile support further dose escalation, affirming differentiated profile Update on the registrational ...
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
NEWTOWN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and develop...
Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL
Preclinical data indicate that narazaciclib shows monotherapy and combination anti-tumor activity in ibrutinib-sensitive and resistant cells and xenograft models
Onconova Expands Leadership Team with Two Key Appointments
Dr. Victor Moyo named Chief Medical Officer Meena Arora joins as Vice President Global Medical Affairs and R&D NEWTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX...
Promising Preclinical Narazaciclib Data Presented at MCL Meeting
Data for Mantle cell lymphoma (MCL) presented in Ireland on Oct. 7, 2023 Additional studies support broad potential, especially in cyclin-dependent cancers
Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress
NEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developi...
Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
NEWTOWN, Pa., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developi...
Onconova Therapeutics, Inc. (ONTX) Q2 2023 Earnings Call Transcript
Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Dr. Steve Fruchtman - President and CEO ...